Premium
Estrogen receptor‐β modulates synthesis of bone matrix proteins in human osteoblast‐like MG63 cells
Author(s) -
Cao Lihuan,
Bu Rongfa,
Oakley Jennifer I.,
Kalla Sara E.,
Blair Harry C.
Publication year - 2003
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.10486
Subject(s) - estrogen , estrogen receptor , osteoblast , endocrinology , medicine , osteoprotegerin , estrogen receptor alpha , chemistry , rankl , osteoclast , estrogen receptor beta , microbiology and biotechnology , bone cell , biology , receptor , in vitro , biochemistry , activator (genetics) , cancer , breast cancer
Abstract Estrogens have complex effects on the skeleton, including regulation of modeling and maintenance of bone mass, which vary with cell type and developmental stage. Osteoblasts are key regulators of skeletal matrix synthesis and degradation. However, whether osteocytes, osteoblasts or earlier progenitors mediate estrogen effects, and the importance of estrogen receptors (ERs) α and β, remain unclear. To address estrogen response in human cells closely related to secretory osteoblasts, we studied MG63 cells with ERα or ERβ reduced to low levels by stable transfection of antisense plasmids. Collagen and alkaline phosphatase expression increased with estrogen in wild‐type and ERα‐suppressed cells, but not in ERβ‐suppressed cells. Matrix secretion occurs as osteoblasts cease dividing, and, in keeping with this, cell proliferation was reduced by estrogen except in ERβ‐antisense cells. No effects of estrogen on wild type or ER‐suppressed cells were seen in expression of BMP 2, the BMP antagonist noggin, or Indian hedgehog, products that regulate differentiation of osteoblasts. In contrast to expectations that estrogen would modulate bone degradation, RANKL, CSF‐1, and osteoprotegerin did not respond measurably to estrogen, regardless of ER status. In keeping with this result, estrogen response was not observed in assays of osteoclast development from CD14 cells supported by wild‐type or ER‐silenced MG63 cells. Since estrogens are major regulators of bone degradation in vivo, estrogen effects on osteoclasts may depend on interaction with stimuli present in bone but absent in the model studied. cDNA hybridization showed that additional estrogen‐binding proteins including ERRα and BCAR3 were expressed by MG63, but estrogen effects in ERβ‐silenced cells were small, so these proteins are either minor regulators in MG63 cells, or act in concert with stimuli in addition to estrogen. We conclude that, in the MG63 cell line, estrogen increases synthesis of matrix proteins via ERβ, and that, in the absence of additional stimuli, these cells are not major mediators of estrogen effects on osteoclast differentiation. Further, ERα is probably much more important in earlier stages of skeletal development, such as growth plate response, than in osteoblasts. J. Cell. Biochem. 89: 152–164, 2003. © 2003 Wiley‐Liss, Inc.